Rheumatoid Arthritis Clinical Trial
Official title:
Immune Response to Varicella Zoster Vaccination (ZOSTAVAX) in Subjects With Rheumatoid Arthritis
Herpes Zoster (shingles) is caused by reactivation of latent varicella zoster virus (VZV)
that usually occurs decades following initial exposure. The risk of developing shingles
increases with age. Shingles presents as a painful, itchy blistering rash that usually
involves a single portion of the skin and lasts about 7-10 days. The risk of developing
shingles increases with age in healthy people, and has been shown in some studies to be
increased in people with rheumatoid arthritis and other autoimmune diseases.
Zostavax, a live-attenuated vaccine against the varicella zoster virus, was first approved by
the FDA for the prevention of Shingles among people 60 years and older, and is now approved
for use in people aged 50 years and older. Because rheumatoid arthritis and some of the
medications used to treat rheumatoid arthritis can impair the body's immune system, it is not
known how much of an immune response can be generated in people with rheumatoid arthritis.
The goals of this study are to measure the immune response after standard vaccination with
Zostavax in people with rheumatoid arthritis in comparison to people with healthy immune
systems. All participants will be 50 years old or older, and subjects with rheumatoid
arthritis will not be eligible if they are taking certain biologic medications, including TNF
inhibitors (Etanercept or Adalimumab). Ten healthy subjects and 10 subjects with rheumatoid
arthritis will all receive a single vaccination with Zostavax, then will be followed for 12
weeks to assess the immune response and for the development of local rash or other potential
side effects.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
| Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
| Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
| Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
| Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
| Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
| Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
| Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
| Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
| Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
| Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
| Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
| Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
| Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
| Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
| Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
| Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus
|
Phase 1 | |
| Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
| Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
| Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |